Holders — by stockHoldings — by fund
Catalio Capital Management, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001958125
$532.1M
disclosed book value
39
positions
10.4%
largest position share
Positions, as of 2026-06-30
top 39 of 39 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | AVLNAVALYN PHARMACEUTICALS INC | 1.7M | $55.2M | 10.4% |
| 2 | JNJJOHNSON & JOHNSON | 138,946 | $35.3M | 6.6% |
| 3 | GILDGILEAD SCIENCES INC | 269,309 | $34.0M | 6.4% |
| 4 | BBIOBRIDGEBIO PHARMA INC | 455,041 | $33.9M | 6.4% |
| 5 | SNDXSYNDAX PHARMACEUTICALS INC | 1.2M | $26.6M | 5% |
| 6 | DFTXDEFINIUM THERAPEUTICS INC | 562,672 | $26.5M | 5% |
| 7 | BMYBRISTOL-MYERS SQUIBB CO | 412,961 | $23.8M | 4.5% |
| 8 | PBLSPARABILIS MEDICINES INC | 824,043 | $22.6M | 4.2% |
| 9 | NTRANATERA INC | 82,181 | $22.3M | 4.2% |
| 10 | INCYINCYTE CORP | 191,627 | $21.7M | 4.1% |
| 11 | SEPNSEPTERNA INC | 536,152 | $18.0M | 3.4% |
| 12 | MLYSMINERALYS THERAPEUTICS INC | 648,722 | $17.5M | 3.3% |
| 13 | HTFLHEARTFLOW INC | 583,055 | $17.1M | 3.2% |
| 14 | CRVSCORVUS PHARMACEUTICALS INC | 1.1M | $16.1M | 3% |
| 15 | GPCRSTRUCTURE THERAPEUTICS INC | 276,550 | $14.8M | 2.8% |
| 16 | PTGXPROTAGONIST THERAPEUTICS INC | 106,799 | $13.1M | 2.5% |
| 17 | IRONDISC MEDICINE INC | 159,384 | $11.7M | 2.2% |
| 18 | EWEDWARDS LIFESCIENCES CORP | 124,778 | $11.3M | 2.1% |
| 19 | AXSMAXSOME THERAPEUTICS INC. | 43,182 | $10.6M | 2% |
| 20 | RAREULTRAGENYX PHARMACEUTICAL IN | 316,252 | $10.6M | 2% |
| 21 | KLRAKAILERA THERAPEUTICS INC | 468,750 | $10.3M | 1.9% |
| 22 | KPTIKARYOPHARM THERAPEUTICS INC | 940,855 | $9.2M | 1.7% |
| 23 | ODTXODYSSEY THERAPEUTICS INC | 457,839 | $8.6M | 1.6% |
| 24 | ASCENDIS PHARMA A/S | 31,759 | $8.5M | 1.6% |
| 25 | KARDKARDIGAN INC | 312,500 | $7.5M | 1.4% |
| 26 | ELDNELEDON PHARMACEUTICALS INC | 1.7M | $6.7M | 1.3% |
| 27 | FDMT4D MOLECULAR THERAPEUTICS IN | 471,254 | $6.3M | 1.2% |
| 28 | MANEVERADERMICS INC | 45,856 | $5.6M | 1.1% |
| 29 | DYNDYNE THERAPEUTICS INC | 244,929 | $5.4M | 1% |
| 30 | GUTSFRACTYL HEALTH INC | 6.2M | $4.9M | 0.9% |
| 31 | IMCRIMMUNOCORE HLDGS PLC | 148,045 | $4.7M | 0.9% |
| 32 | DNTHDIANTHUS THERAPEUTICS INC | 32,941 | $3.2M | 0.6% |
| 33 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 318,407 | $2.4M | 0.5% |
| 34 | TARAPROTARA THERAPEUTICS INC | 520,148 | $2.0M | 0.4% |
| 35 | HYPRHYPERFINE INC | 1.3M | $1.8M | 0.3% |
| 36 | ATAIATAIBECKLEY INC | 196,858 | $1.0M | 0.2% |
| 37 | MGXMETAGENOMI THERAPEUTICS INC | 528,993 | $629,502 | 0.1% |
| 38 | OMOUTSET MED INC | 118,279 | $510,965 | 0.1% |
| 39 | FTHFAETH THERAPEUTICS INC | 14,718 | $367,950 | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.